Zastaprazan is under clinical development by Onconic Therapeutics and currently in Phase III for Corrosive Esophagitis (Erosive Esophagitis). According to GlobalData, Phase III drugs for Corrosive Esophagitis (Erosive Esophagitis) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Zastaprazan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zastaprazan overview
Zastaprazan (Jaqbo, On-Cab, Qzetas) acts as an anti-ulcer agent. It is formulated as film coated tablets for the oral route of administration. Jaqbo is indicated for the treatment of erosive gastroesophageal reflux disease (GERD) in adults.
Zastaprazan is under development for the treatment of gastroesophageal reflux disease (GERD), gastric ulcers and unspecified gastrointestinal disorders. It is administered through oral route as capsule and tablet. The drug candidate is a new molecular entity (NME), it is a potassium-competitive acid blocker (P-CAB).that acts by targeting potassium transporting ATPase alpha.
Onconic Therapeutics overview
Onconic Therapeutics., is a provider of drug development services. The company is headquartered Republic of Korea (South Korea).
For a complete picture of Zastaprazan’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
